Capula Management’s Heron Therapeutics HRTX Stock Holding History

Capula Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,105	Closed	-$157K	–	943
2021 Q2	$157K	Buy	+10,105	New	+$161K	﹤0.01%	715

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Capula Management's HRTX Position: Q3 2021 in Review

Capula Management sold out of Heron Therapeutics (HRTX) in Q3 2021, closing a stake of 10,105 shares — an estimated $157K sold.

Capula Management first reported a position in HRTX in Q2 2021 and held it in 1 quarter. The position peaked at $157K in Q2 2021. 197 funds tracked by Wall St. Rank hold HRTX as of Q3 2021.

Capula Management reported no remaining Heron Therapeutics position as of Q3 2021 after selling out during the quarter.
Capula Management sold 10,105 Heron Therapeutics shares in Q3 2021, an estimated $157K.
Capula Management first reported a position in Heron Therapeutics in Q2 2021 and held it in 1 quarter.
Capula Management's Heron Therapeutics position peaked at $157K in Q2 2021.
197 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2021.

Based on Capula Management's 13F filing for Q3 2021, filed 15 Nov 2021.